Modified RGD Radiopharmaceutical for Integrin αvβ3-Targeted Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional radiolabeled cyclic RGD monomer peptides exhibit low tumor uptake, quick blood clearance, and high organ uptake, complicating synthesis and increasing cost, while combination therapies like PD-1/PD-L1 blockade therapy have limited efficacy, and the synergy of targeted radiotherapy and immunotherapy is not fully explored.
Innovation Solution
A structurally modified RGD polypeptide linked with a bifunctional chelator and radionuclide forms a complex that enhances tumor uptake and stability, combined with PD-1/PD-L1 immune checkpoint inhibitors for targeted radiotherapy and immunotherapy, utilizing 177Lu-DOTA-A-L-3PRGD2 for enhanced imaging and treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If conventional radiolabeled cyclic RGD monomer peptides are used, then the synthesis is simple, but the tumor uptake is low and blood clearance is quick
Solution Approach 1:
The patent combines RGD monomer peptides with multimeric structures to create composite radiopharmaceuticals. These composite structures integrate multiple RGD units with multimeric scaffolds, achieving both high tumor uptake through multiple integrin binding sites and sufficient stability for clinical use, while maintaining relatively simple synthesis protocols
2Quantity of substance
If the degree of multimerization of RGD polypeptides is increased, then the tumor uptake is improved, but the uptake in kidneys, liver and lungs increases significantly
Solution Approach 1:
The patent applies local quality by strategically positioning RGD binding sites on the multimeric structure to target tumor-specific integrin αvβ3 receptors. The multimeric design concentrates the therapeutic effect locally at the tumor site through specific molecular recognition, while the controlled structure prevents excessive distribution to normal organs, thereby improving the therapeutic index
3Stability of the object's composition
If the degree of multimerization of RGD polypeptides is increased, then the stability is improved, but the synthesis complexity and cost increase
Solution Approach 1:
The patent segments the multimeric RGD structure into modular components that can be synthesized separately and then assembled. This segmentation approach allows for standardized production of individual RGD units and multimeric scaffolds, reducing overall synthesis complexity and cost while maintaining the stability benefits of multimerization
4Reliability
If PD-1/PD-L1 blockade therapy is used, then the immune response is activated, but the objective response rate is only about 30%
Solution Approach 1:
The patent merges targeted radiotherapy with PD-1/PD-L1 immune checkpoint blockade therapy in a combination treatment regimen. The radiolabeled RGD multimers deliver localized radiation to tumors while the PD-1/PD-L1 inhibitor activates systemic immune responses. This merging of local and systemic therapeutic mechanisms achieves synergistic effects, significantly improving objective response rates beyond what either therapy can achieve alone
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified RGD polypeptide complex achieves high tumor uptake and extended half-life, activates anti-tumor immune responses, and synergizes with immunotherapy to effectively treat integrin αvβ3-positive tumors, with improved imaging and therapeutic efficacy.
Implementation Method 1
When the labelled complex is a therapeutic complex, the labelled complex can be used for treating a tumor
Implementation Method 2
RGD can bind specifically to the integrin αvβ3 and therefore the RGD-type molecular probes designed by using the specific binding of the RGD to the integrin αvβ3 has been investigated and utilized extensively
Implementation Method 3
A structurally modified RGD polypeptide linked with a bifunctional chelator and radionuclide forms a complex
Data Source
AI summary
A pharmacological composition contains a complex having a structurally modified RGD polypeptide a radionuclide. This pharmacological composition is useful for diagnosis or treatment of the integrin αvβ3-positive tumors. The pharmacological composition may further contain an immunotherapeutic medicament and an optional nanoantibody molecular imaging probe. Treatment with a PD-L1 blockade after the targeted radioactive therapy can archive the optimal synergic efficacy. Moreover, with administration of PD-1 or PD-L1 nanoantibody molecular imaging probe, expression of PD-1 or PD-L1 in the tumor after targeted radiotherapy can be observed.